CHMP recommends Janssen/Astex's Dacogen for AML
This article was originally published in Scrip
Executive Summary
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has given a positive opinion for Dacogen (decitabine), an Astex Pharmaceuticals drug licensed to Janssen, in acute myeloid leukaemia (AML).
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.